Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna Inc (NASDAQ: MRNA) shares have tanked more than 20% from record levels noted on Monday after reporting market-beating quarterly results last week. Much of the decline was driven from BofA's Geoff Meacham, who said in a note yesterday that the biotech firm should be about 75% below its current price.

Analyst: “no other company will have an mRNA booster like Moderna”

The shares of Moderna Inc (NASDAQ: MRNA) increased by over 5% during intraday trading. This is why it happened.

Moderna Shares Increase Over 5% Intraday: Why It Happened

BioNTech SE

Pfizer

Stocks of mRNA-based COVID-19 vaccine makers, MRNA, PFE and BNTX fall for two consecutive days on bearish sentiments after a strong rally as well as probable side-effects of their vaccines.

mRNA COVID-19 Vaccine Makers Lose Steam After Strong Rally

Microsoft

Netflix

NIKE

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified Netflix among others.

AI Identifies Netflix Among Today's Trending Stocks

Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.

Do Options Traders Know Something About Moderna (MRNA) Stock We Don't?

Wall Street analysts appear less keen than retail traders on vaccine makers such as Moderna, after a breakneck rally over the last year.

Moderna was the most-bought stock for retail traders in the week leading up to its 16% single-day plunge

As one of the leaders of messenger RNA (mRNA) vaccine technology, there is certainly a lot to like about Moderna's future.

Moderna: The Rally Is Over For Now

The pre-print study suggested the Pfizer vaccine was 34 points less effective in preventing infection last month, at least in one state, NBC New York reports.

Mayo Clinic: COVID Breakthrough Risk May Be Much Lower With Moderna Than Pfizer

The study charted the effectiveness of mRNA vaccines given out in the Mayo Clinic Health System in Minnesota between January and July.

Pfizer's vaccine efficacy dropped to 42% while Moderna's was at 76% when the Delta variant became the dominant strain, study says

Editas Medicine

Editas could be an attractive acquisition candidate for the big vaccine maker.

Will Moderna Buy Editas Medicine to Jump Into Gene Editing?

The U.S. Food and Drug Administration is expected to authorize on Thursday a third dose of the Pfizer Inc. (NYSE:PFE)-BioNTech SE (NASDAQ:BNTX) and Moderna Inc. (NASDAQ:MRNA) COVID-19 vaccines for certain people with weakened immune systems, the New York Times reported. What Happened: The decision to expand the emergency use of the two COVID-19 vaccines will cover organ transplant recipients and people whose immune systems are similarly compromised, the report noted, citing people familiar with the plans.

FDA Expected To Authorize Moderna, Pfizer COVID-19-Vaccine Third Doses For Some People Today: NYT

The stock price of Moderna Inc (NASDAQ: MRNA) fell 15.64%. This is why it happened.

MRNA Stock Price Fell 15.64%: Why It Happened

Pfizer's stock also took a hit on Wednesday.

Moderna Crash Wipes Out Over $20 Billion In Market Value After Concerns Stock Is Overhyped

The EU's drug regulator is looking at reports about skin rash and kidney problems.

Moderna, BioNTech tumble 19% amid report the EU is looking into COVID vaccine side effects

Amazon

Johnson & Johnson

Lockheed Martin

Zoetis

McDonald's

These seven stocks to buy right now for a bear market are also generally strong in bull markets. Their resistance is the key element.

7 Best Bear Market Stocks to Buy Now in Preparation for a Downturn

The sell-off in Moderna, Inc. (NASDAQ: MRNA)'s shares intensified Wednesday amid fears concerning stretched valuation and potential side effects from its mRNA vaccine. Moderna shares closed at a record high of $484.47 on Monday, propelled by optimism concerning its vaccine against the novel coronavirus.

Why Moderna Stock Is Continuing Its Losses Today

Advanced Micro Devices

Goldman Sachs

Cloudflare

NVIDIA

Block

These stocks to buy can provide investors with big and consistent returns as they continue to defy expectations and soar to new heights. The post 7 Unstoppable Stocks to Buy to Power Up Your Portfolio appeared first on InvestorPlace.

7 Unstoppable Stocks to Buy to Power Up Your Portfolio

Atea Pharmaceuticals

Merck

Sorrento Therapeutics Inc

Vaxart

You may have thought the moment of relevancy for these biotech stocks was over, but the Delta variant has changed their prospects. The post 7 Biotech Stocks to Buy Amid the Delta Variant's Onslaught appeared first on InvestorPlace.

7 Biotech Stocks to Buy Amid the Delta Variant's Onslaught

Moderna Inc. shares MRNA, -15.79% tumbled 16% Wednesday to put them on track for their biggest percentage decline since May of 2020, according to Dow Jones data. The stock has now fallen for four of the past five days and has lost more than 20% in a two-day period.

Moderna shares slide 16% after bearish BofA note, putting them on track for biggest percentage decline since May 2020

Coinbase

Veteran trader David Green was back live trading on Benzinga Monday morning, and the long-time trader made some moves.  Green pointed out the strong trend of Moderna Inc (NASDAQ: MRNA) Tuesday morning.

Why Former NYSE Trader Bought Coinbase, AMD and Moderna Stock Tuesday Morning

Moderna Inc (NASDAQ: MRNA) has signed a memorandum of understanding, a non-legally binding agreement with the Canadian government to build a state-of-the-art messenger RNA (mRNA) vaccine manufacturing facility. While the details are not disclosed, the idea is to eventually use the site to supply Canada with direct access to rapid pandemic response capabilities, including the Company's two-dose COVID-19 vaccine.

Moderna Outlines Plans For mRNA Vaccine Manufacturing Plant In Canada

Shares of Moderna Inc. have soared so much that the biotechnology company's valuation is “unjustifiable on a fundamental basis,” said analyst Geoff Meacham on Tuesday, as his analysis suggests the stock should be priced about 75% below current levels.

The Ratings Game: Moderna's stock price is ‘ridiculous,' says BofA analyst

"To justify $200 billion in value, one has to assume 1 to 1.5 billion doses of COVID-19 vaccine each year from 2022-2038," BofA argued.

'From unreasonable to ridiculous': Here's why Moderna is set to fall 76%, according to Bank of America

Moderna, Inc. (NASDAQ:MRNA) shares have rallied since the start of July, rendering the valuation unattractive and "ridiculous," according to a BofA Securities analyst.  The Moderna Analyst: Geoff Meacham maintained an Underperform rating on Moderna with a $115 price target.

Moderna Analyst: Valuation Of COVID-19 Stock 'Ridiculous'

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna and Canada announce collaboration to bring mRNA manufacturing to Canada.

News for Moderna Stock (MRNA)